Cytotoxics and High Potency Manufacturing
- All
- APIs
- Aseptic Processing
- cGMP Manufacture
- Cleaning Validation
- Clinical Trial Materials
- Cytotoxics and High Potency Manufacturing
- Excipients
- Extractables and Leachables
- Facilities
- Fill/Finish
- Lyophilization
- Parenterals
- Process Development
- Process Validation
- Risk Management
- Scale-up/Technology Transfer
- Solid Dosage/Creams/Ointments
-
Cytotoxics and High Potency Manufacturing
HPAPI Technology Trends
Expanding HPAPI sector driving innovation in containment technologyMichael Avraam, Global Product Manager, ChargePoint Technology 10.10.18
-
Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
IDIFARMA Adds Spray Drying for Highly Potent Drugs
GEA Niro Mobile Minor equipment up to Category 4 OEL/OEB now operational10.08.18
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Industry News
Cambrex Upgrades API Mfg. Facilities in Milan
$3 million investment will include installation of new 12,000 liter reactor10.08.18
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Industry News
Lonza Expands HPAPI Capacity
Will add two new manufacturing suites at its Visp site for the manufacture of ADC payloads10.08.18
-
APIs | Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
Evonik Completes €36M Expansion
Adds HPAPI, mPEGs and continuous processing at multiple production sites in the U.S. and Europe09.19.18
-
APIs | Cytotoxics and High Potency Manufacturing
HPAPI Technology Evolution
Handling of high potency compounds for API and DP from development on a laboratory scale and scale-up to commercial.Martina Kotthaus, Jeff Dinyer, Anil Kane and Marvin Faber, Patheon, part of Thermo Fisher Scientific 09.11.18
-
APIs | Cytotoxics and High Potency Manufacturing
HPAPI Market Trends
Rising demand for targeted cancer and other treatments driving HPAPI growth.Nigel Walker, That’s Nice/Nice Insight 09.11.18
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Excipients | Facilities | Industry News
AGC Expands CDMO Services
Increases GMP-compliant synthetic pharmaceutical intermediate and active ingredient production capacity tenfold07.12.18
-
cGMP Manufacture | Cytotoxics and High Potency Manufacturing
Minakem to Open New Containment Facility for HPAPI Production
CDMO has entered final qualification run for a new closed-controlled environment production facility in BelgiumVideos
-
APIs | Cytotoxics and High Potency Manufacturing | Facilities | Industry News | Scale-up/Technology Transfer
Cambrex Invests $5M in New Lab Expansion
To add capability and capacity at Karlskoga, Sweden facility05.31.18
-
APIs | Cytotoxics and High Potency Manufacturing | Drug Development | Industry News
Cambrex Completes Pilot Plant Expansion at High Point
Begins construction of a new $24 million facility at Charles City, IA plant for the manufacture of HPAPIs05.15.18
-
Cytotoxics and High Potency Manufacturing | Industry News
PCI Launches High Containment Packaging at Ireland Site
Latest strategic initiative expands High Containment Operations services04.25.18
-
Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Idifarma Expands High Potent Capabilities
Niche CDMO adds spray drying for highly potent drugs03.29.18
-
Analytical Services | Breaking News | Cytotoxics and High Potency Manufacturing | Industry News
PCI Bolsters Analytical Capabilities
Significant expansion of analytical laboratories at its center of excellence for contained manufacturing03.20.18
-
Analytical Services | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Drug Development | Formulation Development | Industry News | Solid Dosage/Creams/Ointments
Hovione Expands Capacity
Plans for future expansion at its sites in Portugal, Ireland and New Jersey03.19.18
-
Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News | Solid Dosage/Creams/Ointments
Lonza Expands Encapsulation and HPAPI Capabilities in North America
A new suite added that facilitates encapsulation of highly potent compounds02.21.18
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Avista Doubles API Mfg. Capacity at Colorado Facility
Upgrades support processing of potent compounds11.17.17
-
Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
PCI Expands Highly Potent Capabilities for Clinical Services
Makes another investment in fully contained Xcelodose 600S technology11.10.17
-
Breaking News | Clinical Trial Materials | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Capsugel Expands Capabilities
To offer more clinical trial services as well as high potency compounds11.01.17
-
Breaking News | Cytotoxics and High Potency Manufacturing | Drug Development | Facilities | Industry News | Inspections | Solid Dosage/Creams/Ointments
Almac Passes MHRA Inspection at Charnwood Facilities
Can develop, make and pack non-potent and potent, solid orals for clinical trials and commercial supply10.23.17
